Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Preliminary Evaluation of the <sup>211</sup>At-Labeled PARP Inhibitor [<sup>211</sup>At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Molecular pharmaceutics·2026
Same author

First-in-human evaluation of [<sup>211</sup>At]YF2 in patients with metastatic castration-resistant prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same author

<sup>191</sup>Pt-labeled trithiol-Hoechst-PSMA: preliminary evaluation of conjugates designed for delivery to genomic DNA of PSMA-positive cancers.

EJNMMI radiopharmacy and chemistry·2026
Same author

Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [<sup>211</sup>At]YF2.

European journal of nuclear medicine and molecular imaging·2025
Same author

Structural analysis of nanobody interactions with their prostate-specific membrane antigen binding epitopes.

International journal of biological macromolecules·2025
Same author

Trithiol ligand provides tumor-targeting <sup>191</sup>Pt-complexes with high molar activity and promising in vivo properties.

Nuclear medicine and biology·2025

Related Experiment Video

Updated: Jun 16, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Astatine Radiopharmaceuticals: Prospects and Problems.

Ganesan Vaidyanathan1, Michael R Zalutsky

  • 1Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.

Current Radiopharmaceuticals
|February 13, 2010
PubMed
Summary

Targeted radiotherapy using alpha-particle emitters like astatine-211 shows promise for treating residual cancer. Researchers are exploring various astatine-211 labeled compounds for improved efficacy and safety in cancer treatment.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Jun 16, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical therapy
  • Oncology

Background:

  • Targeted radiotherapy with alpha-particle emitters offers advantages for treating minimal residual disease.
  • Astatine-211 is a promising alpha-particle-emitting radionuclide due to its chemical properties and radiobiological benefits.
  • Radioiodination chemistry can be adapted for incorporating astatine-211 into biomolecules.

Purpose of the Study:

  • To review the chemistry and radiobiological advantages of astatine-211 labeled radiopharmaceuticals.
  • To discuss the biodistribution, microdosimetry, and pharmacokinetic modeling of these agents.
  • To highlight challenges and potential adverse effects of astatine-211 based therapies.

Main Methods:

  • Review of existing literature on astatine-211 radiopharmaceuticals.
  • Analysis of chemical incorporation methods and in vitro/in vivo studies.
  • Discussion of clinical evaluation of selected agents.

Main Results:

  • A wide spectrum of compounds labeled with astatine-211 have been investigated, including small molecules, peptides, and proteins.
  • At least two astatine-211 labeled agents have advanced to clinical trials.
  • Alpha-particles offer radiobiological advantages including high linear energy transfer (LET) and short tissue range.

Conclusions:

  • Astatine-211 labeled radiopharmaceuticals are attractive for targeted radiotherapy of minimal residual disease.
  • Further research is needed to overcome challenges like radiolysis and in vivo stability.
  • Careful consideration of biodistribution and potential adverse effects is crucial for clinical application.